Tiered quality control in urine-derived iPSC reprogramming determines pan-cancer modeling reliability

Urine-derived induced pluripotent stem cells (UDiPSCs) provide a noninvasive cell source for patient-specific tumor modeling. Whether this platform can be deployed reliably across solid tumor types remains unsettled as reprogramming protocols are inconsistent, genomic stability data are uneven, and no quality control (QC) framework has been designed for cross-tumor use. We evaluated published UDiPSC reprogramming workflows against the operational demands of pan-cancer modeling. Using Failure Mode and Effects Analysis, we screened 14 process variables and retained seven critical control points, each with a scoring rationale, measurement method, and working control threshold. These critical control points form a three-tier QC architecture (Bronze, Silver, and Gold) corresponding to research-grade, enhanced research-grade, and good manufacturing practice-compatible translational use. Acceptance, release, and tier-upgrade rules are specified for each tier. This review also distinguishes three deployment modes that are often conflated: engineered oncogenic models based on UDiPSC-derived organoids, host-background comparators (patient-matched normal tissue), and pharmacological context models for absorption, distribution, metabolism, and excretion) and host–tissue toxicity. Because each mode imposes different QC requirements, tier selection must reflect the intended use. Without tiered QC and explicit performance boundaries, UDiPSC-based pan-cancer modeling cannot meet the reproducibility expectations now applied to functional biomarker platforms by regulators and clinicians.